UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy
Phase 4
Completed
- Conditions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2013-11-15
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 14
- Registration Number
- NCT00630357
S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
Phase 4
Completed
- Conditions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2013-11-15
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 1541
- Registration Number
- NCT00630968
A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
Phase 4
Completed
- Conditions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2013-11-15
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 35
- Registration Number
- NCT00631150
Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 3
- Registration Number
- NCT00630630
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-03-04
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 69
- Registration Number
- NCT00628108
Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2011-09-12
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 227
- Registration Number
- NCT00624351
A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2020-07-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 596
- Registration Number
- NCT00621959
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 173
- Registration Number
- NCT00619801
Alprostadil in Maculopathy Study (AIMS)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 37
- Registration Number
- NCT00619229
Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 216
- Registration Number
- NCT00615615
© Copyright 2024. All Rights Reserved by MedPath